Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000562774
Ethics application status
Approved
Date submitted
8/05/2013
Date registered
17/05/2013
Date last updated
23/07/2018
Type of registration
Retrospectively registered
Titles & IDs
Public title
Renal Sympathectomy in dialysis-dependent patients to reduce cardiovascular risk. A pilot study
Query!
Scientific title
Renal endoluminal denervation to reduce sympathetic overdrive in dialysis-dependent patients.
Query!
Secondary ID [1]
282467
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1142-8219
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
End Stage Kidney Disease
289086
0
Query!
Condition category
Condition code
Renal and Urogenital
289426
289426
0
0
Query!
Kidney disease
Query!
Cardiovascular
289427
289427
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
289428
289428
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The denervation procedure itself involves an endovascular catheter-based approach to disrupt renal sympathetic nerves using radiofrequency (RF) ablation. This is a single intervention, which takes approximately 40 minutes for the proceedure in the cardiology angiography suite. This procedure will by performed by Assoc Prof G Wilkins. Data will be collected at baseline (over a week prior to the procedure) and following renal denervation at 1, 3, and 12 months. The impact of renal denervation will be measured by changes in blood pressure; cardiac function by way of holter monitoring and echocardiographic measurement of left ventricular function; multiunit postganglionic sympathetic nerve activity (MSNA) will be recorded through the use of microneurography in the peroneal nerve; circulating plasma catecholamines as an indirect marker of sympathetic activity
Query!
Intervention code [1]
287113
0
Treatment: Devices
Query!
Comparator / control treatment
An open interventional study with each participant acting as their own control. Each individual will have baseline studies of blood pressure, cardiac function (holter monitoring for 48 hours to assess beat to beat variability and echocardiographic measurements of left ventricular function), MSNA studies, blood samples taken to measure circulating plasma catecholamines. Following the baseline measurements, the individual will undergo the endoluminal ablation of their renal sympathetic nerves by radiofrequency ablation. They will then be followed closely for the next 12 months, with repeat measurements of the above parameters at 1 month, 3 months and 12 months.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
289529
0
Changes in renal sympathetic nerve activity as measured by multiunit sympathetic nerve activity
Query!
Assessment method [1]
289529
0
Query!
Timepoint [1]
289529
0
Baseline prior to the procedure, then at 1month, 3 months and 12 months after the procedure
Query!
Secondary outcome [1]
302688
0
Changes in cardiac function as assessed by beat to beat variability on holter monitoring, echocardiographic changes in left ventricular function and volume, and changes in blood pressure.
Query!
Assessment method [1]
302688
0
Query!
Timepoint [1]
302688
0
Baseline prior to the procedure and then at 1 month, 3 months, 12 months after the procedure
Query!
Secondary outcome [2]
302689
0
Changes in circulating plasma catecholamines and beat to beat variability in heart rate as markers of systemic sympathetic activity after the intervention compared to baseline values.
Query!
Assessment method [2]
302689
0
Query!
Timepoint [2]
302689
0
Baseline prior to the procedure and at 1 month. 3 months, 12 months after the procedure.
Query!
Eligibility
Key inclusion criteria
Age > 18 and able to give consent.
On dialysis for at least 3 months.
Clinically stable with no evidence of fluid overload, recent myocardial ischaemia or heart attack.
Blood pressure > 130/90 despite medications.
They must have intact native renal kidneys
Query!
Minimum age
8
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients with significant renovascular abnormalities will not permitted to undergo the intervention. Anatomic abnormalities including multiple main renal arteries, short length main renal arteries, failed renal transplant, are exclusion criteria.
Inability to give consent.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A pilot feasibility study using the individual as their own control. Participants will be enrolled from the dialysis unit and out patient clinics.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
An open pilot study.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Statistical Assessment: MSNA levels from baseline to the above time points (1,3, 12 months) will be evaluated to calculate mean change, as well as 95% CIs. This change will be assessed by repeated-measures ANOVA with pairwise comparison of significant values. A 2-tailed paired t test of P<0.05 to be regarded as statistically significant. Other measures such as 24 hour BP, holter monitoring, plasma catecholamines, LV Mass, etc will be compared in a similar manner.
This is a pilot study. There has been no such previous interventions in this group of patients. As such there is no data to inform a power calculation. This pilot study is to generate such data to inform a properly conducted randomised intervention trial in the future.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
28/02/2013
Query!
Actual
5/03/2013
Query!
Date of last participant enrolment
Anticipated
31/07/2013
Query!
Actual
23/07/2013
Query!
Date of last data collection
Anticipated
Query!
Actual
9/12/2014
Query!
Sample size
Target
15
Query!
Accrual to date
Query!
Final
9
Query!
Recruitment outside Australia
Country [1]
5069
0
New Zealand
Query!
State/province [1]
5069
0
Otago
Query!
Funding & Sponsors
Funding source category [1]
287247
0
Self funded/Unfunded
Query!
Name [1]
287247
0
Query!
Address [1]
287247
0
Query!
Country [1]
287247
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Otago
Query!
Address
PO Box 56
Dunedin 9054
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
285998
0
None
Query!
Name [1]
285998
0
Query!
Address [1]
285998
0
Query!
Country [1]
285998
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289226
0
Lower South Regional Ethics Committee
Query!
Ethics committee address [1]
289226
0
C/- Ministry of Health
PO Box 5013
Wellington 6145
Query!
Ethics committee country [1]
289226
0
New Zealand
Query!
Date submitted for ethics approval [1]
289226
0
Query!
Approval date [1]
289226
0
17/05/2012
Query!
Ethics approval number [1]
289226
0
LRS/12/05/012
Query!
Summary
Brief summary
Sudden cardiac death accounts for 26-45% of cardiovascular deaths in patients on dialysis. Sympathetic overactivity from the diseased kidneys is thought to contribute substantially to the high risk of cardiac events. The Australasian Kidney Trials Network (AKTN) have initiated a feasibility study of beta blocker therapy (BLOCADE) to test the tolerability of carvidolol in dialysis patients, with the view to a full study investigating sympathetic blockade on cardiac events in dialysis patients. Renal sympathetic denervation by radiofrequency ablation is a new novel alternative to medical therapy to reduce sympathetic overactivity. It would be logical to compare ß blocker therapy to renal denervation in dialysis patients in a head to head study. However, it is necessary to test the feasibility of renal denervation in this high risk group and to obtain appropriate data that would accurately inform end points and surrogate markers of the endpoints. The surrogate end points are changes in blood pressure, reduction in anti-hypertensive medications, changes in heart rate, changes in sympathetic nerve activity measured directly by microneurography and indirectly by changes in circulating neuro-hormones.
This application is for a feasibility study to inform scientific committee of the AKTN to allow a well designed intervention study to reduce sudden cardiac death in a very high risk population, that is patients on dialysis.
Query!
Trial website
Query!
Trial related presentations / publications
Endovascular renal denervation in end-stage kidney disease patients: Cardiovascular
protection – A proof-of-concept study
Neil A. Hoye, MBBS, Luke C. Wilson, PhD, Gerard T. Wilkins, MBChB, FRACP,
David L. Jardine, MBChB, FRACP, Tracey T. Putt, MBChB, MMed Sci, FRACP,
Ari Samaranayaka, PhD, John B.W. Schollum, MBChB, FRACP, Robert J. Walker,
MBChB, MD, FRACP
PII: S2468-0249(17)30111-0
DOI: 10.1016/j.ekir.2017.04.012
Reference: EKIR 154
To appear in: Kidney International Reports
Received Date: 5 February 2017
Revised Date: 17 April 2017
Accepted Date: 26 April 2017
Query!
Public notes
Query!
Contacts
Principal investigator
Name
39878
0
Prof Robert Walker
Query!
Address
39878
0
Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054
Query!
Country
39878
0
New Zealand
Query!
Phone
39878
0
+64274359552
Query!
Fax
39878
0
Query!
Email
39878
0
[email protected]
Query!
Contact person for public queries
Name
39879
0
Prof Robert Walker
Query!
Address
39879
0
Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054
Query!
Country
39879
0
New Zealand
Query!
Phone
39879
0
+64274359552
Query!
Fax
39879
0
Query!
Email
39879
0
[email protected]
Query!
Contact person for scientific queries
Name
39880
0
Prof Robert Walker
Query!
Address
39880
0
Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054
Query!
Country
39880
0
New Zealand
Query!
Phone
39880
0
+64274359552
Query!
Fax
39880
0
Query!
Email
39880
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF